114 - ALK INHIBITORS SAFETY PROFILE IN PEDIATRIC PATIENTS TREATED FOR AN ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA: REAL LIFE EXPERIENCE AMONG A FRENCH COHORT.

Authors :: d'Hautefeuille, C.
Abbou, S.
El-Gourari-Miaz, L.
Lambilliotte, A.
Renard, C.
Landman-Parker, J.
Gourdon, S.
Metayer, L.
Leblanc, T.
Pacquement, H.
Rabian, F.
Verschuur, A.
Brasme, J.
Millot, F.
Pagnier, A.
Buchbinder, N.
Rorhlich, P.
Minard-Colin, V.
Brugières, L.
Ducassou, S.
Source :: Leukemia Research. 2022 Supplement, Vol. 121, pS68-S69. 2p.
Publication Year :: 2022

Subjects :: *ANAPLASTIC large-cell lymphoma
*CHILD patients
*ANAPLASTIC lymphoma kinase

Full Text Access

Tools